Wall Street Starts Coverage on PLSE and ENGN: What You Need to Know
Mizuho and Jefferies initiate coverage on Pulse Biosciences and enGene, highlighting growth potential, strong clinical data, and upcoming catalysts in biotech.
/ 2 items
Mizuho and Jefferies initiate coverage on Pulse Biosciences and enGene, highlighting growth potential, strong clinical data, and upcoming catalysts in biotech.
Raymond James upgrades enGene to Strong Buy with $27 target as detalimogene shows 62% complete response rate in bladder cancer trial with excellent tolerability.